The global Genomics market size is expected to reach
USD 27.6 billion by 2025, according to a new report by Grand View Research,
Inc., progressing at a CAGR of 9.7% during the forecast period. Over the past
few years, there have been significant changes in disease management processes
due to simultaneous advancements in genomics and personalized medicine. There
has been a gradual growth in usage of genomic studies in clinical practices,
which is reflected by growing trend of targeted therapies.
Results from genomic studies
enable a better understanding of diseases and underlying mechanisms for
researchers, physicians, and consumers. This facilitates evidence-based
decision-making and thus, helps improve personalized treatment regime. In
addition, technological advancements in data analysis tools are motivating
healthcare community to create precision-based therapies from surplus,
available DNA data.
Advancements in genomics and
associated technologies are significantly impacting crop genetics.
Technological advancements in sequencing facilitate genomes &
transcriptomes sequencing for several crops. Although a reference genome exists
for several crops, resequencing and gene expression studies are required for
in-depth study of key genes contributing to desired trait. Implementation of
this information in crop breeding helps in development of advanced crops.
Companies are involved in
strategic alliances with global as well as local entities to boost their
revenue generation and enhance their share in the market. For instance, in
March 2017, Foundation Medicine collaborated with Bristol-Myers Squibb Company.
Through the collaboration, the latter was able to deploy former’s molecular
information solutions and comprehensive genomic profiling for identification of
predictive biomarkers, such as Microsatellite Instability (MSI) and Tumor
Mutational Burden (TMB), to accelerate its immunotherapy clinical trials. Such
initiatives are aimed at increasing the adoption of genomic information in
cancer management.
Browse Research Report on Genomics Market:
Further Key Findings From the Report Suggest:
·
High volume requirement and
high cost of specific reagents contribute to substantial revenue growth. Companies
are incorporating the trend of offering varied reagents that simplify workflow
process
·
NGS-based services hold a major
share in the genomics services segment due to their rapid adoption of whole
genome sequencing and application of sequence databases for disease screening
and prognosis
·
Biomarkers exhibit high
clinical potential and efficiency across treatment of wide range of diseases.
Use of predictive biomarkers for diagnosis and monitoring take cancer
eradication a step further. Moreover, organizations and programs such as
National Biomarker Development Alliance (NBDA) are actively participating in
development of novel biomarkers for cancer diagnosis
·
Growing interest of
pharmaceutical and biotechnology companies in genomics is expected to drive the
market in the coming years.
·
As patients are focusing more
on their health, direct-to-consumer (DTC) laboratory testing is increasingly
gaining popularity. DTC genetic tests enable consumers to access information
about their genetics without necessarily including healthcare professionals in
the process
·
Asia Pacific is the most
promising region, exhibiting a CAGR of 12.7% during the forecast period. The
growth of the region can be attributed to improving healthcare infrastructure
·
Some of the key players in the
market are BGI; Agilent Technologies; Thermo Fisher Scientific, Inc.; Bio-Rad
Laboratories, Inc.; Foundation Medicine, Inc., 23andMe, Inc.; Danaher;
Illumina, Inc.; Pacific Biosciences; Oxford Nanopore Technologies.; F.
Hoffmann-La Roche Ltd.; and Myriad Genetics, Inc.
·
Market participants are engaged
in making the technology available to users at a lower price and in a compact
form.
View more
reports of this category by Grand View Research at
Grand View Research has segmented the global genomics
market on the basis of product & service, application & technology,
end-use, and region:
Genomics Product and Service Outlook (Revenue, USD
Million, 2014 - 2025)
·
Products
o Instruments/Systems/Software
o Consumables & Reagents
·
Services
o Core Genomics Services
o NGS-based Services
o Biomarker Translation Services
o Computational Services
o Others
Genomics Application & Technology Outlook (Revenue,
USD Million, 2014 - 2025)
·
Functional Genomics
o Transfection
o Real-time PCR
o RNA interference
o Mutational analysis
o SNP analysis
o Microarray analysis
·
Epigenetics
o Bisulfite sequencing
o Chromatin immunoprecipitation (ChIP & ChIP-Seq)
o Methylated DNA immunoprecipitation (MeDIP)
o High resolution melt (HRM)
o Chromatin accessibility assays
o Microarray analysis
·
Pathway Analysis
o Bead-based analysis
o Microarray analysis
o Real-time PCR
o Proteomics tools (2-D PAGE; yeast 2-hybrid studies)
·
Biomarker Discovery
o Mass spectrometry
o Real-time PCR
o Microarray analysis
o Statistical analysis
o Bioinformatics
o DNA sequencing
·
Others
Genomics End-use Outlook (Revenue, USD Million, 2014 -
2025)
·
Clinical Research
·
Academic and Government
Institutes
·
Hospitals and Clinics
·
Pharmaceutical and
Biotechnology Companies
·
Other End Users
View
press release of this research report by Grand View Research:
About Grand View Research
Grand View Research, Inc. is a U.S. based market research
and consulting company, registered in the State of California and headquartered
in San Francisco. The company provides syndicated research reports, customized
research reports, and consulting services. To help clients make informed
business decisions, we offer market intelligence studies ensuring relevant and
fact-based research across a range of industries, from technology to chemicals,
materials, and healthcare.
